Drug Trial Radar · NCT00863707
A Study of the Safety and Tolerance of Regadenoson in Subjects With Renal Impairment
Last checked: Nov 20, 2026Latest source record: May 18, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
511
Actual
Start
Apr 2009
Primary completion
Dec 2009
Study completion Dec 2009
Sponsor
- Lead sponsor
- Astellas Pharma IncAstellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Mar 18, 2009
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is intended to assess the safety and tolerance of regadenoson in subjects with renal impairment.
Conditions
- Kidney Diseases
- Coronary Artery Disease
Interventions
RegadenosonDrug
IV
PlaceboDrug
IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subject With Serious Treatment Emergent Adverse Events (TEAE)Time frame: 24 hours post dose
Locations
41 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Anniston, Alabama
Site not named
Little Rock, Arkansas
Site not named
Bell Gardens, California
Site not named
Fullerton, California
Site not named
Garden Grove, California
Site not named
Los Angeles, California
Site not named
Los Angeles, California
Site not named
Mission Viejo, California
Site not named
Oakland, California
Site not named
Roseville, California
Site not named
Santa Ana, California
Site not named
Newark, Delaware
Site not named
Wilmington, Delaware
Site not named
Fort Lauderdale, Florida
Site not named
Miami, Florida
Site not named
Orlando, Florida
Site not named
Trinity, Florida
Site not named
Winter Park, Florida
Site not named
Ellijay, Georgia
Site not named
Chicago, Illinois
Site not named
Auburn, Maine
Site not named
Detroit, Michigan
Site not named
Flint, Michigan
Site not named
Minneapolis, Minnesota
Site not named
Ridgewood, New Jersey
Site not named
Somerset, New Jersey
Site not named
New York, New York
Site not named
Springfield Gardens, New York
Site not named
Springfield, Ohio
Site not named
Oklahoma City, Oklahoma
Site not named
Bend, Oregon
Site not named
Duncansville, Pennsylvania
Site not named
Indiana, Pennsylvania
Site not named
Tyrone, Pennsylvania
Site not named
Wyomissing, Pennsylvania
Site not named
Charleston, South Carolina
Site not named
Spartanburg, South Carolina
Site not named
Knoxville, Tennessee
Site not named
Houston, Texas
Site not named
Houston, Texas
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.